Latisse approved for treatment of hypotrichosis of the eyelashes

Latisse approved for treatment of hypotrichosis of the eyelashes
Latisse approved for treatment of hypotrichosis of the eyelashes

The FDA has approved Allergan's Latisse (bimatoprost ophthalmic solution) 0.03% for the treatment of hypotrichosis of the eyelashes. Latisse is only available through a doctor as a once-daily prescription treatment applied to the upper eyelashes with a sterile, single-use-per-eye applicator. It enhances eyelash prominence as measured by increases in length, thickness, and darkness of eyelashes in as little as 8 weeks, with full results in 16 weeks. Eyelashes will gradually return to where they were prior to treatment over a period of weeks to months if therapy is discontinued.

Latisse is expected to be available in the first quarter of 2009.

For more information call (800) 433-8871 or visit www.latisse.com.